Theracos
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, Theracos sits in the top decile of US sponsors by registered trial count (#801 of 15,742 sponsors by registered trial count).
Theracos: 18 sponsored US clinical trials, none currently recruiting.
Theracos sponsors 18 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 18 completed. 6 of these trials are in Phase 3-4 (later-stage) and 12 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Type 2 Diabetes Mellitus, with 1 trials.
Top-decile sponsor footprint
Theracos ranks in the top decile of sponsors by registered trial count (#801 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
18 of 18 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (100.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
18 total, page 1 of 1
Safety and Efficacy of Bexagliflozin in Subjects With Moderate Hepatic Impairment
NCT03557658
Safety and Efficacy of Bexagliflozin Compared to Placebo as Add-on Therapy to Metformin in Type 2 Diabetes Subjects
NCT03259789
An Integrated Assessment of the Safety and Effectiveness of Bexagliflozin for the Management of Essential Hypertension
NCT03514641
Safety and Efficacy of Bexagliflozin Compared to Sitagliptin as Add-on Therapy to Metformin in Type 2 Diabetes Subjects
NCT03115112
Study to Evaluate Effects of Probenecid, Rifampin and Verapamil on Bexagliflozin in Healthy Subjects
NCT03296800
Bexagliflozin Drug/Drug Interaction Study With Digoxin
NCT03197324
Bexagliflozin Drug/Drug Interaction Study With Exenatide Injection
NCT03167411
Interaction of Bexagliflozin With Metformin, Glimepiride and Sitagliptin
NCT02956044
Safety and Efficacy of Bexagliflozin in Type 2 Diabetes Mellitus Patients With Moderate Renal Impairment
NCT02836873
Safety and Efficacy of Bexagliflozin Compared to Glimepiride as Add-on Therapy to Metformin in Type 2 Diabetes Subjects
NCT02769481
Study to Evaluate the Effects of a High-Fat Meal on Bexagliflozin in Healthy Subjects
NCT02820298
Safety and Efficacy of Bexagliflozin as Monotherapy in Patients With Type 2 Diabetes
NCT02715258
Bexagliflozin Efficacy and Safety Trial
NCT02558296
A Dose Range Finding Study to Evaluate the Effect of Bexagliflozin Tablets in Subjects With Type 2 Diabetes Mellitus
NCT02390050
Efficacy and Safety of EGT0001442 in Patients With Type 2 Diabetes Mellitus
NCT01377844
Safety and Efficacy Study of EGT0001442 in Subjects With Type 2 Diabetes Mellitus
NCT01029704
Safety, Tolerability and Pharmacokinetics Study of EGT0001474 in Subjects With Type 2 Diabetes
NCT00924053
Study to Determine the Safety, Tolerability, and Pharmacokinetic (PK) Profile of EGT0001474 in Healthy Volunteers
NCT00854113
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 8 |
| Phase 2 | 4 |
| Phase 3 | 6 |
Therapeutic Areas
How the Theracos early-phase archive is shaped
18 indexed studies, none listed as recruiting (0% open); 18 completed (100%).
Phase mix: 6 late (III/IV) vs 12 early (I/II) (early-phase heavy).
Top condition: Type 2 Diabetes Mellitus (1 trial), 0 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Theracos: archived-pipeline peers nationwide
Peers matched on 18 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Theracos sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 18 archived trials
- ADC Therapeutics S.A. · 18 trials · 11% recruiting
- Akros Pharma · 18 trials · 0% recruiting
- AO Clinical Investigation and Publishing Documentation · 18 trials · 0% recruiting
- AO Innovation Translation Center · 18 trials · 33% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Theracos page
18 registered trials is a research-attention snapshot, not an endorsement of Theracos or any single study.
- None of Theracos's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Type 2 Diabetes Mellitus is the condition Theracos studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Type 2 Diabetes Mellitus trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Theracos pipeline card: 18 registered trials from official public datasets.Report a data error.